Loading
A phase 1/2 trial of Test product HY0001a for injection in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.
A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07069062 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 261 participants planned, started 2025-07-21 and due to reach its primary completion in 2027-06. Interventions recorded: Test product HY0001a for injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/